The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1648
April 18, 2022
View Complete Issue         Table of Contents 2019 
Issue 1648
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
In Brief: Expanded Heart Failure Indication for Empagliflozin (Jardiance)
April 18, 2022 (Issue: 1648)
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance – Boehringer Ingelheim) was approved by the FDA in 2021 to reduce the risk of hospitalization for heart failure (HF) and cardiovascular death in patients with heart...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1648
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.